Am Fam Physician. 2023;108(1):93-94
Author disclosure: No relevant financial relationships.
| Drug | Dosage | Dose form | Cost* |
|---|---|---|---|
| Tirzepatide (Mounjaro) | 2.5 mg subcutaneously once weekly for four weeks, followed by 5 mg once weekly | Injection pen (pre-filled single-dose pen, 0.5 mL): 2.5, 5, 7.5, 10, 12.5, and 15 mg | $1,000 for four 2.5-mg injection pens |
| Titration: increase dosage by 2.5 mg every four weeks to a maximum dosage of 15 mg once weekly if additional glycemic control is needed |
Tirzepatide (Mounjaro) is labeled for the treatment of type 2 diabetes mellitus in adults as an adjunct to lifestyle modifications. It is the first agonist that targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptors.1 This dual effect is hypothesized to impact glycemic control and weight loss more than GLP-1 receptor agonism alone due in part to the prevalence of glucose-dependent insulinotropic polypeptide receptors in adipose tissue and the brain.
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
